MedTrace Logo

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

NCT00124943 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2012-04-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis following de novo stenting or following angioplasty for in-stent restenosis.

Conditions

  • Coronary Restenosis

Interventions

DRUG

Nanoparticle Paclitaxel

Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.

Sponsors & Collaborators

  • Celgene Corporation

    lead INDUSTRY

Principal Investigators

  • Jose' Iglesias, MD · Celgene Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2009-08-31
Completion
2009-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00124943 on ClinicalTrials.gov